Journal of Cancer Science and Research
Open Access

Faculte de medecine, Universite Mohammed VI des Sciences de la Sante. Casablanca, Morocco

Publications

• Research Article   
  Metastatic hormone-sensitive prostate cancer: A Systematic Review of the Value of Current Therapies
  Author(s): Wafaa Kaikani*, Mohammed sqalli Houssaini and Khalid Hadadi
  
  PROSTATE cancer (PC) is the second most frequent cancer in males. Based on GLOBOCAN 2018 estimates, 1,356,176 new cases of prostate cancer and a mortality of 378,553 are expected in 20201. Despite an overall 5-year survival rate of 98.2%, mHSPC has a dismal 30% 5-year survival rate2. Metastatic hormone-sensitive prostate cancer (mHSPC) is the disease space whereby men have metastatic prostate cancer and have never received (ie. are sensitive to) androgen deprivation therapy (ADT). mHSPC previously constituted ~30% of prostate cancer cases , however, from 2004-2012 secondary to PSA testing, the estimate was ~5% of cases in USA3. Many experts in the field suggest that with decreased PSA screening over the last few years, as a result of the United States Preventative Services Task Force (USPSTF) Grade D recommendation for PSA screening (subsequently upgraded to C 4), that these estimates.. View More»
  

  Abstract PDF